Ever-Changing Paradigms in Cervical Cancer Screening: A GLIMPSE INTO THE FUTURE

DATE: Thursday, April 14, 2016
TIME: 6:00 PM - 8:00 PM
LOCATION: Versailles Ballroom | Hilton New Orleans Riverside

DINNER WILL BE SERVED TO ALL PARTICIPANTS

FACULTY
Warner K. Huh, MD
University of Alabama at Birmingham
BIRMINGHAM, ALABAMA

Mark Schiffman, MD, MPH
National Cancer Institute
BETHESDA, MARYLAND

Register onsite or now at OmniaEducation.com/CervicalCancer
Walk-ins welcome

ACCREDITATION STATEMENT  The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT  The Omnia-Prova Education Collaborative, Inc. designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COMMERCIAL SUPPORT  This activity is supported by an independent educational grant from BD Life Sciences.
Table of Contents

General Information...................................................................................................................................................................4

Hotel Floor Plan..........................................................................................................................................................................5

Meeting Information
  Meeting Competencies and Objectives...................................................................................................................................6
  Course Educational Methods......................................................................................................................................................6
  Continuing Medical Education.................................................................................................................................................7
  Management of Disclosure of Interest and Contributed Fund.................................................................................................8

Speakers and Moderators..........................................................................................................................................................10

Annual Meeting Program..........................................................................................................................................................11

Posters.........................................................................................................................................................................................16

Exhibitors..................................................................................................................................................................................19

Exhibitor Floor Plan.................................................................................................................................................................23

Sponsors.....................................................................................................................................................................................23
Registration Hours

The ASCCP Registration Desk is located on the Third Level, except for Wednesday between 7:00 AM - 4:00 PM. During this time, registration will be in the Foyer of Gran Salon A. Registration will be open during the following hours:

Wednesday, April 13: 7:00 AM - 6:30 PM
Thursday, April 14: 7:00 AM - 5:00 PM
Friday, April 15: 7:00 AM - 6:30 PM
Saturday, April 16: 7:00 AM - 1:30 PM

Exhibit/Poster Hours

Thursday, April 14

Breakfast: 7:00 AM - 8:00 AM
AM Break: 9:30 AM - 10:00 AM
Lunch: 12:00 PM - 1:30 PM
PM Break: 3:00 PM - 3:30 PM
Welcome Reception: 5:00 PM - 6:00 PM

Friday, April 15

Breakfast: 7:00 AM - 8:00 AM
AM Break: 10:00 AM - 10:30 AM
Lunch: 12:15 PM - 1:30 PM
PM Break: 3:00 PM - 3:30 PM
Cases Over Cocktails: 5:00 PM - 6:30 PM

Saturday, April 16

Breakfast: 7:00 AM - 8:00 AM
AM Break: 10:30 AM - 10:55 AM

Cell Phone Protocol

Please ensure that cell phone ringers are turned off or muted during all sessions.

Lost & Found

Please stop by the ASCCP Registration Desk if you have lost or found an item during the course of the Meeting. You may also wish to check with hotel security regarding lost items.

Name Badges

Name badges must be worn to access the Exhibit Hall, educational sessions and social events.

Photograph/Video Release

Photographs and/or video taken at ASCCP’s 2016 Annual Meeting may be used in future ASCCP marketing, publicity, promotions, advertising, social networking, and training activities. By registering and attending, you agree to allow ASCCP to use the photographs and/or video materials.

Audio/Video Recording Devices

The use of personal tape recorders, video cameras, or flash photography are not permitted during sessions.

Children

Children and babies are not permitted in the Exhibit Hall or educational sessions.

Wireless Internet

As an ASCCP attendee, you will receive complimentary high-speed internet in your guest room. Guest room access covers most public areas. It will not work in meeting rooms or pre-function areas.

Hotel Information

Hilton New Orleans Riverside
Two Poydras Street
New Orleans, Louisiana, 70130, USA
Phone: 504-561-0500
Check-in: 3:00 PM
Check-out: 12:00 PM
Download the ASCCP2016 Mobile App

- Browse Sessions
- View Abstracts
- Create Itinerary
- Connect with Attendees
- Access New Orleans Map
- And much more!
Meeting Competencies and Objectives

The Annual Meeting provides learners with a review of current-ly available screening and management guidelines along with the most up-to-date advances in the prevention, screening, diagnosis and treatment of lower genital tract disorders with an emphasis on human papillomavirus (HPV)-associated diseases and cervical cancer. It is designed to improve medical knowledge, practice-based learning, patient outcomes, and/or systems-based practice.

The Annual Meeting is targeted to all who are interested in improving clinical outcomes of lower genital tract disorders — this includes health care providers from a variety of different disciplines including gynecologists, family physicians, gynecologic oncologists, pathologists, dermatologists who deal with vulvar conditions, advanced practice clinicians (e.g. nurse practitioners, physician assistants, nurse midwives, nurses, etc.), residency directors of obstetrics/gynecology and family medicine.

Upon completion of this educational activity and its post-test and evaluation tool, the learner should be able to:

- Understand the biology, epidemiology, natural history, and immune response to HPV, in association with the development of lower genital tract neoplasia. Also understand the societal costs associated with genital HPV infections (medical knowledge, practice-based learning);

- Manage positive cytology and HPV test results, high risk HPV genotype results, and histologically confirmed lower genital tract neoplasia reflecting current and future patient risk of high grade neoplasia (medical knowledge; practice-based learning; patient outcomes);

- Apply colposcopy to the diagnosis and management of lower genital tract disorders in ways that reflect its usefulness and maximum benefits while minimizing potential harms and recognizing limitations of the method (medical knowledge; system-based practice; patient outcomes);

- Successfully apply consensus guidelines for cervical cancer screening and management of cervical abnormalities to women in both the general population and in special circumstances using evidence derived from epidemiological, natural history and observational studies (systems-based practice, practice-based learning, patient outcomes, medical knowledge);

- Successfully apply management strategies to women with lower genital tract disorders in special populations, especially young women, postmenopausal, and underserved women, with insight into special problems encountered including HPV-associated anal disease (medical knowledge, practice-based learning, patient outcomes, systems-based practice);

- Integrate into practice new insights from the latest research on prevention, diagnosis and management of lower genital tract disorders (medical knowledge, practice-based learning);

- Diagnose and treat lower genital tract disorders to include cervical, vaginal, vulvar, and anal intraepithelial neoplasia, genital warts, and other vulvar and vaginal diseases (medical knowledge, practice-based learning, systems-based practice);

- Discuss strategies for prevention, screening, early detection and management of HPV-associated oropharyngeal disorders.

Course Educational Methods

Lectures: Each day, the learners will attend general plenary sessions related to their areas of interest. Each session will conclude with a question and answer period led by the presenter(s) to reinforce core concepts. Throughout the lectures and question and answer periods, faculty members utilize an Audience Response System. The faculty uses these group responses to readdress items not answered correctly by the target goal percentage. This immediate feedback helps course attendees identify their own weaknesses and allows them to follow up with the faculty onsite.

Clinical Abstracts: The learners will have the ability to present and hear abstracts of clinical research results, utilizing both oral presentation and poster formats.

Panel Discussions: For selected topics, learners will direct questions to panels of experts on how to integrate reported advances into their practices. Experts will present their varying evidence-based perspectives so that learners can determine what may be best practice in their setting.

The lectures will be available for download until May 16, 2016 at www.asccp.org/2016annualmeeting/lectures.
Continuing Medical Education

ACCME Accreditation
The American Society for Colposcopy and Cervical Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ASCCP 2016 Annual Meeting was planned and produced in accordance with the ACCME’s Essential Areas and Elements and Updated Criteria (see www.accme.org).

Continuing Medical Education Credits

ASCCP: The American Society for Colposcopy and Cervical Pathology designates this live activity for a maximum of 24 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A maximum of 17.25 AMA PRA Category 1 Credits™ can be claimed for attendance at Annual Meeting.

CME Credit for Pre-Course Courses

Colposcopy:Case Based: Attendees will receive a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

What Everyone Ought to Know about Vulvovaginal Disease: Attendees will receive a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educate the Educators: Attendees will receive a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Obtaining Continuing Medical Education Credit

To complete this program successfully and receive credit and a certificate of attendance, participants must:

• Read the program educational objectives and review and utilize the final program;
• Sign in each day at the ASCCP registration desk and attend the program (to include abstracts, plenary and afternoon sessions);
• Complete the post-conference assessment (15 minute online survey);
• Claim credits via ASCCP webpage

CME Certificates

CME certificates will be available online after completion of the evaluation. During the meeting, if you notice an error on your name badge, registration letter, or any other ASCCP materials, please stop by the registration desk so that we may correct.

ASCCP Courses

Comprehensive Colposcopy
Beginning/intermediate colposcopist or those in needs of updates—Gain additional knowledge on Cervical Cancer Screening & Management Guidelines, new concepts about HPV screening and triage, treatment methods, and HPV epidemiology.

Providence, RI

High Resolution Anoscopy
This course is for those participating in the health care of patients who have increased risk for anal cancer including MSM, men and women with HIV disease, and women with HPV-associated lower genital tract disease.

October 26-29, 2016
Phoenix, Arizona

July 28-30, 2016
Providence, RI

For more information and to register go to www.asccp.org
Management of Disclosure of Interest and Contributed Fund

As an accredited provider of CME credit, ASCCP is required to comply with the ACCME’s Standards for Commercial Support and has implemented a management process to ensure that anyone who is in a position to affect the content of the educational activity (e.g., faculty, planners, etc.) has disclosed to us all relevant financial relationships with any commercial interest and has ensured that those relationships do not influence presentation materials. All faculty have agreed to base their presentations on best available evidence. ASCCP discloses to learners any financial relationship(s) to healthcare-related commercial interests existing within the past 12 months to include the following information: 1) the name of the individual; 2) the name of the commercial interest; and, 3) the nature of the relationship the person has with each commercial interest. Program directors review presentation materials for possible bias prior to the program, and potential conflicts of interest are resolved prior to the presentation. Any discussion of off-label use of products is noted when appropriate, as is discussion of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Disclosures of these commitments and/or relationships are published in the final program materials and provided from the podium so those participants in the activity may formulate their own judgments regarding the presentation(s). The program directors and co-directors also monitor presentations for bias and intervene as appropriate to provide balance. Under ASCCP policy, anyone declining either to disclose or amend material to eliminate potential bias identified by the program directors are replaced.

The disclosures listed below are all reported disclosures of interest or potential conflicts from the 12 months preceding this activity:

### Commercial Disclosures

ASCCP expresses deep appreciation to Merck for their generous educational grant support of the 2016 Annual Meeting.

#### COI Disclosure Key

<table>
<thead>
<tr>
<th>Medical Advisor (A)</th>
<th>Advisory Board (AB)</th>
<th>Book Author or CD Author (BA)</th>
<th>Book Editor (BE)</th>
<th>Clinical Trial Pathologist (CTP)</th>
<th>Clinical Trial Support (CTS)</th>
<th>Clinical Trial Consultant (CTC)</th>
<th>Consultant (C)</th>
<th>Consulting Medical Director (CMD)</th>
<th>Consulting Pathologist (CP)</th>
<th>Data Steering Committee (DSM)</th>
<th>Dividends (D)</th>
<th>Educational Grant (EG)</th>
<th>Equipment Support (E)</th>
<th>Employee (EM)</th>
</tr>
</thead>
</table>
2016 AM COI Disclosures
(Moderators, Speakers Education Committee Chairs, Staff)

Jeff Andrews, MD (Editor-In-Chief) - No financial relationships or conflict of interest to disclose
Barbara S. Apgar, MD, MS - Elsevier Publishing (R) (BA); SABK Inc. (R). (BA)
Kevin A. Ault, MD - Hologic (CTS) (PI); Merck & Co, Inc (CTS) (PI); Roche (CTS) (PI)
Robert A. Bednarczyk, PhD - No financial relationships or conflict of interest to disclose
James R. Bentley, MD - Merck & Co., Inc (H) (SB); Astra Zenica (H) (AB)
J. Michael Berry-Lawhorn, MD - No financial relationships or conflict of interest to disclose
Lilly Brotons (Staff) - No financial relationships or conflict of interest to disclose
Erin T. Carey, MD, MSCR - No financial relationships or conflict of interest to disclose
P. Patricia Cason, FNP - Merck & Co., Inc (H) (SB)
Kerry O. Curtis (Staff) - No financial relationships or conflict of interest to disclose
Lisa M. DeGrave (Staff) - No financial relationships or conflict of interest to disclose
Kathleen P.L. Dwyer (Staff) - No financial relationships or conflict of interest to disclose
Michael A. Gold, MD - No financial relationships or conflict of interest to disclose
Richard S. Guido, MD, CIP - No financial relationships or conflict of interest to disclose
Robin Heine (Staff) - No financial relationships or conflict of interest to disclose
Beth C. Huff, MSN, FNP - No financial relationships or conflict of interest to disclose
Warner K. Huh, MD - THEVAC (S) (C)
Naomi Jay, PhD, RN, NP - No financial relationships or conflict of interest to disclose
Sarah Jones (Staff) - No financial relationships or conflict of interest to disclose
Michelle J. Khan, MD, MPH - Cepheid (T) Investigator’s Meeting
L. Stewart Massad, MD - No financial relationships or conflict of interest to disclose
Edward J. Mayeaux, Jr., MD - No financial relationships or conflict of interest to disclose
Anna-Barbara Moscicki, MD - Merck (H) (AB)
Edward E. Partridge, MD - No financial relationships or conflict of interest to disclose
Carlos H. Perez, MD - MSD (H) (SB); Roche (H) (SB); Euroetika (H) (SB)
Rebecca Perkins, MD - No financial relationships or conflict of interest to disclose
Michael S. Policar, MD, MPH - No financial relationships or conflict of interest to disclose
Walter Prendeville, MD - Utah Medical (R.). (I)
Chanise Queen (Staff) - No financial relationships or conflict of interest to disclose
Cynthia A. Rasmussen, MD - Pfizer Corp. (SH)
Kimberly Sabatano (Staff) - No financial relationships or conflict of interest to disclose
Mark Schiffman, MD, MPH - Roche (RS) (RE); BD (RS) (RE)
Elizabeth A. Stier, MD - No financial relationships or conflict of interest to disclose
Colleen K. Stockdale, MD, MS - No financial relationships or conflict of interest to disclose
Michelle M. Szymanski, RNC, MSN, OGNP - Myriad Genetics (H) (SB)
Candice A. Tedeschi, NP - No financial relationships or conflict of interest to disclose
Alan G. Waxman, MD, MPH - No financial relationships or conflict of interest to disclose
Li-Huh Wei, MD - No financial relationships or conflict of interest to disclose
Nicolas Wentzensen, MD, PhD, MS - Employed by the National Cancer Institute (NCI) which has received cervical cancer screening assay in-kind or at reduced cost from BD, Cepheid, Hologic, and Roche
Melinda Wharton, MD, PhD - No financial relationships or conflict of interest to disclose
J. Nicole Windsor - No financial relationships or conflict of interest to disclose
Alisha Yocum (Staff) - No financial relationships or conflict of interest to disclose

(2016 Planning Committee)

Jeff Andrews, MD (Editor-In-Chief) - No financial relationships or conflict of interest to disclose
Kevin A. Ault, MD - Hologic (CTS) (PI); Merck & Co, Inc (CTS) (PI); Roche (CTS) (PI)
Lilly Brotons (Staff) - No financial relationships or conflict of interest to disclose
Kerry O. Curtis (Staff) - No financial relationships or conflict of interest to disclose
Beth C. Huff, MSN, FNP - No financial relationships or conflict of interest to disclose
Chanise Queen (Staff) - No financial relationships or conflict of interest to disclose
Colleen K. Stockdale, MD, MS - No financial relationships or conflict of interest to disclose
Alisha Yocum (Staff) - No financial relationships or conflict of interest to disclose
Jeff Andrews, MD  
Physician Associates  
Bethesda, MD

Barbara S. Apgar, MD  
University of Michigan Medical Center  
Ann Arbor, MI

Kevin A. Ault, MD  
University of Kansas Medical Center  
Kansas City, KS

Robert A. Bednarczyk, PhD  
Winship Cancer Institute of Emory University  
Atlanta, GA

James Bentley, MBChB FRCSC  
Dalhousie University, Halifax  
Nova Scotia, Canada

J. Michael Berry-Lawhorn, MD  
University of California, San Francisco  
San Francisco, CA

Fabrizio Bogliatto, MD  
Chivasso Civic Hospital  
Torino, Italy

Erin Carey, MD MSCR  
University of North Carolina  
Chapel Hill, NC

P. Patricia Cason, FNP  
University of California, Los Angeles  
School of Nursing  
Los Angeles, CA

Mark Einstein, MD  
Rutgers  
Newark, NJ

Michael Gold, MD  
University of Oklahoma  
School of Community Medicine  
Tulsa, OK

Richard S. Guido, MD, CIP  
Magee Womens Hospital  
Pittsburgh, PA

Beth C. Huff, MSN, FNP  
Nashville, TN

Warner K. Huh, MD  
University of Alabama at Birmingham  
Birmingham, AL

Naomi Jay, NP, PhD  
University of California, San Francisco Dysplasia Clinic  
San Francisco, CA

Michelle J. Khan, MD, MPH  
University of Alabama at Birmingham  
Birmingham, AL

L. Stewart Massad, MD  
Washington University School of Medicine in St Louis  
St. Louis, MO

Edward J. Mayeaux, Jr., MD  
University of South Carolina School of Medicine  
Columbia, SC

Anna-Barbara Moscicki, MD  
University of California, Los Angeles  
Los Angeles, CA

Edward E. Partridge, MD  
University of Alabama at Birmingham  
Birmingham, AL

Carlos H. Perez, MD  
Hospital de San Jose  
Bogota, Colombia

Rebecca B. Perkins, MD, MSc  
Boston Medical Center  
Boston, MA

Michael Policar, MD, MPH  
University of California, San Francisco  
San Francisco, CA

Walter Prendiville, MD  
International Agency for Research on Cancer (IARC)  
Dublin, Ireland

Cynthia Rasmussen, MD  
Beth Israel Deaconess Medical Center  
Burlington, MA

Mark Schiffman, MD, MPH  
National Cancer Institute  
Rockville, MD

Elizabeth A. Stier, MD  
Boston University Medical Center  
Boston, MA

Colleen K. Stockdale, MD, MS  
University of Iowa  
Iowa City, IA

Michelle M. Szymanowski, RNC, MSN, OGNP  
Southwest Contemporary Women’s Care  
Gilbert, AZ

Candice A. Tedeschi, NP  
Private Practice  
Glen Cove, NY

Alan G. Waxman, MD, MPH  
University of New Mexico School of Medicine  
Albuquerque, NM

Li-Huh Wei, MD  
Peking University People’s Hospital  
Peking, China

Nicolas Wentzensen, MD, PhD  
National Cancer Institute  
Rockville, MD

Melinda Wharton, MD, PhD  
National Center for Immunization and Respiratory Diseases  
Atlanta, GA

J. Nicole Windsor  
Bowie & Jensen, LLC  
Towson, MD
Thursday, April 14, 2016

7:00 AM - 8:00 AM  Napoleon Ballroom
**Breakfast / Visit Exhibits / View Posters**

8:00 AM - 8:15 AM  Jefferson Ballroom
**Annual Meeting Welcome**
**Speakers:** Colleen K. Stockdale, MD, MS
Kevin A. Ault, MD

8:15 AM - 8:30 AM  Jefferson Ballroom
**President’s Welcome**
**Speaker:** Richard S. Guido, MD, CIP

8:30 AM - 9:30 AM  Jefferson Ballroom
**Keynote Lecture: Disparities in Cancer Care Delivery—Is Cervical Cancer the Prototype?**
**Moderator:** Richard S. Guido, MD, CIP
**Keynote Speaker:** Edward E. Partridge, MD

9:30 AM - 10:00 AM  Napoleon Ballroom
**Break / Visit Exhibits / View Posters**

10:00 AM - 11:00 AM  Jefferson Ballroom
**CDC Barriers to Vaccination**
**Moderator:** Richard S. Guido, MD, CIP
**Speaker:** Melinda Wharton, MD, PhD

11:00 AM - 12:00 PM  Jefferson Ballroom
**Oral Abstract Presentations**
**Moderator:** Richard S. Guido, MD, CIP

11:00 AM - 11:15 AM  
HPV/Cytology Cotesting at 3-year Intervals Results in Reduced Yield of Precancer per Screen Over Time
**Presenter:** Michelle Silver, PhD, ScM

11:15 AM - 11:30 AM  
**The Development and Evaluation of a New Solid Media Specimen Transport Card for Population Based Cervical Cancer Prevention**
**Presenter:** Kathryn Maurer, MD

11:30 AM - 11:45 AM  
**The Effects of an Educational Intervention on Self-Sampling for Human Papillomavirus Acceptability: RCT**
**Presenter:** Eribeth Karina Penaranda, MD

11:45 AM - 12:00 PM  
**Cervical Cytology Progression in Women Following Solid Organ Transplant**
**Presenter:** Margaret E. Long, MD

12:00 PM - 1:30 PM  Napoleon Ballroom
**Lunch / Visit Exhibits / View Posters**
**Challenge Bowl**
Watch Residents and new colposcopists take the Colposcopy Challenge during this interactive session.
**Moderator:** Edward J. Mayeaux, Jr., MD

1:30 PM - 3:00 PM  
**Concurrent Session 1: Your Test is Abnormal: Applying Shared Decision Making to Difficult Conversations**
**Jefferson Ballroom**
**Speakers:** P. Patricia Cason, FNP
Michael S. Policar, MD, MPH

**Concurrent Session 2: Oral Abstract Presentations—HPV Vaccine Update**
**Versailles Ballroom**
**Moderators:** L. Stewart Massad, MD
Candice A. Tedeschi, NP

1:30 PM - 1:45 PM  
**Impact of a Prior History of HPV Vaccination on the Prevalence of HPV and Cytological Abnormalities in Women 21-35 Years**
**Presenter:** Thomas C. Wright, Jr, MD

1:45 PM - 2:00 PM  
**Impact of Guideline Changes on CDSS for Cervical Cancer Screening and Surveillance**
**Presenter:** Kathy L. MacLaughlin, MD

2:00 PM - 2:15 PM  
**Impact of Number of HPV Vaccine Doses on Genital Warts Diagnoses Among Urban US Adolescents**
**Presenter:** Rebecca Perkins, MD, MSc
2:15 PM - 2:30 PM
Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia Post-HPV Vaccine Era in New Mexico, 2007-2013
Presenter: Vicki B. Benard, PhD

2:30 PM - 2:45 PM
Risk-based action thresholds for cervical cancer screening and management in two large U.S. practice settings
Presenter: Julia C. Gage, PhD, MPH

2:45 PM - 3:00 PM
The Risk Factors of Progression for HPV 16 Infected Women with ASC-US or LSIL
Presenter: Tae Jin Kim, MD, PhD

Concurrent Session 3: Oral Abstract Presentations—Special Populations/Anal
Rosedown Meeting Room
Moderators: Jeff Andrews, MD
Naomi Jay, PhD, RN, NP

1:30 PM - 1:45 PM
Conservative Treatment of Adenocarcinoma In Situ: Post-Cone Surveillance and Time to Recurrence
Presenter: Ana Milena Angarita, MD

1:45 PM - 2:00 PM
Effect of Structured Guidelines for Immediate LEEP After HSIL Pap on Patient Outcomes
Presenter: Ali McGregor, MD

2:00 PM - 2:15 PM
Evaluation of Risk-Based Colposcopy in the ALTS Trial
Presenter: Angela Hui-Chia Liu, MD

2:15 PM - 2:30 PM
Predictors of Recurrent or Persistent Disease After LEEP Procedure
Presenter: Helen E. Cejtin, MD

2:30 PM - 2:45 PM
Screening for Pre-Invasive and Invasive Glandular Lesions of the Cervix: Pap Test Results and Time to Diagnosis
Presenter: Lea Moukarzel, MD

2:45 PM - 3:00 PM
Sustainable Cervical Cancer Prevention Clinics Using the World Health Organization ‘See and Treat’ Methods: A Five Country Experience
Presenter: Caroline Cristina Nitschmann, MD

3:00 PM - 3:30 PM
Break / Visit Exhibits / View Posters
Napoleon Ballroom

3:30 PM - 5:00 PM
Concurrent Session 1: Comprehensive Colposcopy Skill
Jefferson Ballroom
Speakers: Barbara S. Apgar, MD, MS
Candice A. Tedeschi, NP

Concurrent Session 2: Oral Abstract Presentations
Versailles Ballroom
Moderators: L. Stewart Massad, MD
Michelle M. Szymanowski, RNC, MSN, OGNP

3:30 PM - 3:45 PM
Detection of HPV Infection in Oropharyngeal and Oral Cavity Cancers
Presenter: Elizabeth A. Kostas-Polston, PhD, APRN, WHNP

3:45 PM - 4:00 PM
High-Grade CIN Detected by Colposcopic Directed or Random Biopsy Relative to Patient Age, Cytology, HPV 16, and Lesion Size
Presenter: Ruifang Wu, MD

0:00 PM - 4:15 PM
Inhalant Allergy in Chronic Vaginitis: Diagnoses, Sensitivities, Co-Morbidities and Response to Sublingual Immunotherapy
Presenter: Demetrios S. Theodoropoulos, MD, DSc

4:15 PM - 4:30 PM
Is Negative Co-Testing in HIV+ Women Associated with a Low Three-Year Risk of Cervical Pre-Cancers?
Presenter: Elizabeth A. Stier, MD

4:30 PM - 4:45 PM
Screening for Pre-Invasive and Invasive Glandular Lesions of the Cervix: Pap Test Results and Time to Diagnosis
Presenter: Lea Moukarzel, MD

4:45 PM - 5:00 PM
Virologic Correlates Strongly Support the Use of Composite Cytology-Histology in the Diagnosis of Anal High Grade Squamous Intraepithelial Lesions
Presenter: Richard John Hillman, MD

Concurrent Session 3: Oral Abstract Presentations
Rosedown Meeting Room
Moderators: Jeff Andrews, MD
P. Patricia Cason, FNP

3:30 PM - 3:45 PM
Agreement Between Endocervical Brush and Endocervical Curettage in Patients Undergoing Repeat Endocervical Sampling
Presenter: Meredith Alston, MD

3:45 PM - 4:00 PM
Are Women with Abnormal Pap Smears Being Discharged from Colposcopy too soon?
Presenter: Rachel Kupets, MD

4:00 PM - 4:15 PM
Evaluation of the Practice Patterns of Practitioners Performing Cervical Biopsies
Presenter: Kristen Mosier, MD

4:15 PM - 4:30 PM
Office Hysteroscopy in the Diagnosis of Cervical Intra-Epithelial Neoplasia
Presenter: Ahmad Sameer Sanad

4:30 PM - 4:45 PM
p16 Expression in Colposcopically-Directed and Random Cervical Biopsies of CIN2 and CIN3
Presenter: Cynthia Arvizo, MD

4:45 PM - 5:00 PM
The Study of FRD™ Testing Used in Cervical Cancer Screening
Presenter: Yun Zhao, Professional

5:00 PM - 6:00 PM
Welcome Reception
Napoleon Ballroom

6:00 PM - 8:00 PM
Satellite Symposia w/ Dinner
Sponsored by Omni Education
Ever-Changing Paradigms in Cervical Cancer Screening: A Glimpse into the Future
Versailles Ballroom
Friday, April 15, 2016

7:00 AM - 8:00 AM

**Breakfast / Visit Exhibits / View Posters**
Napoleon Ballroom

**Advance Practice Clinicians Breakfast**
Magnolia Meeting Room
Nurse practitioners, midwives, and Clinicians are invited to participate in this round-table breakfast, which will include a brief program.

**Speakers:**
- Beth C. Huff, MSN, FNP
- Candice A. Tedeschi, NP
- Naomi Jay, PhD, RN, NP

**Practice Management & Employment Law Symposium with Breakfast**
Norwich Meeting Room

**Speaker:** J. Nicole Windsor

8:00 AM - 8:15 AM

**Annual Meeting Welcome**
Speakers: Colleen K. Stockdale, MD, MS
- Kevin A. Ault, MD

8:15 AM - 8:45 AM

**Vaginal Neoplasia-A Common Clinical Dilemma:**
**Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results**

**Moderator:** Edward J. Mayeaux, Jr., MD

**Speaker:** Michelle J. Khan, MD, MPH

8:45 AM - 9:15 AM

**Update on the Management of LSIL & HSIL of the Vulva**

**Moderator:** Edward J. Mayeaux, Jr., MD

**Speaker:** Fabrizio Bogliatto, MD, PhD

9:15 AM - 10:00 AM

**Head and Neck Cancers and HPV**

**Moderator:** Michelle J. Khan, MD, MPH

**Speaker:** Edward J. Mayeaux, Jr., MD

10:00 AM - 10:30 AM

**Break / Visit Exhibits / View Posters**

10:30 AM - 11:30 AM

**Oral Abstract Presentations— Reviewer’s Choice**

**Moderators:**
- Michelle J. Khan, MD, MPH
- Jeff Andrews, MD

11:00 AM - 11:15 AM

**Racial/Ethnic Differences in the Prevalence of Prior HPV Vaccination in Females 18 years of Age in Two Large Integrated Health Care Systems in California**

**Presenter:** Neal M. Lonky, MD, MPH

11:15 AM - 11:30 AM

**Towards an International Consensus of Practice Standards in the Detection of Anal Cancer Precursors**

**Presenter:** Richard John Hillman, MD

11:30 AM - 12:15 PM

**Epidemiology and Sex - HPV - Vaccine**

**Moderator:** Jeff Andrews, MD

**Speaker:** Robert A. Bednarczyk, PhD

12:15 PM - 1:30 PM

**Lunch / Visit Exhibits / View Posters**

1:30 PM - 3:00 PM

**Concurrent Session 1: Emerging Vulvar Treatment Options**

**Moderator:** Colleen K. Stockdale, MD, MS

1:30 PM - 1:50 PM

**Vulvar Regenerative Therapy**

**Speaker:** Cynthia A. Rasmussen, MD

1:50 PM - 2:00 PM

**Questions and Faculty Responses**

2:00 PM - 2:05 PM

**Questions and Faculty Responses**

2:05 PM - 2:15 PM

**The Good and Bad of Cytology and DARE**

**Speaker:** Elizabeth A. Stier, MD

2:15 PM - 2:25 PM

**HRA is the Gold Standard**

**Speaker:** Naomi Jay, PhD, RN, NP

2:25 PM - 2:35 PM

**HPV Testing and P16: What is the Role in Anal Disease**

**Speaker:** J. Michael Berry-Lawhorn, MD
2:35 PM - 2:50 PM
Questions and Faculty Responses

2:50 PM - 3:00 PM
Wrap Up: Determining Female Populations for Screening
Speaker: Anna-Barbara Moscicki, MD

3:00 PM - 3:30 PM
Break / Visit Exhibits / View Posters

3:30 PM - 5:00 PM

Concurrent Session 1: Vulvodynia – Terminology Update
Jefferson Ballroom
Moderator: Barbara S. Apgar, MD, MS

3:30 PM - 4:00 PM
Vulvar Terminology
Speaker: Alan G. Waxman, MD, MPH

4:00 PM - 4:10 PM
Questions and Faculty Responses

4:10 PM - 4:50 PM
Vulvodynia Pain Management
Speaker: Erin T. Carey, MD, MSCR

4:50 PM – 5:00 PM
Questions and Faculty Responses

Concurrent Session 2: Understanding the Practice of HRA
Versailles Ballroom
Moderator: Anna-Barbara Moscicki, MD

3:30 PM - 3:55 PM
HRA Overview
Speaker: Naomi Jay, PhD, RN, NP

3:55 PM - 4:20 PM
What Providers Need to Know About Managing Anal HSIL
Speaker: J. Michael Berry-Lawhorn, MD

4:20 PM - 4:45 PM
What You Can Do Until You Get Trained
Speaker: Elizabeth A. Stier, MD

4:45 PM - 5:00 PM
Summary
Speaker: J. Michael Berry-Lawhorn, MD

5:00 PM - 6:30 PM
Cases Over Cocktails
All attendees are encouraged to come to the exhibit hall for over 100 poster presentations while having appetizers and cocktails. This is a non-cme presentation and will consist of authors being present and ready to receive questions for their posters. Please make sure to come by and have a cocktail while reviewing your colleagues presentations.

Saturday, April 16, 2016

7:00 AM - 8:00 AM
Napoleon Ballroom
Breakfast / Visit Exhibits / View Posters

8:00 AM - 8:10 AM
Jefferson Ballroom
Annual Meeting Welcome
Speakers: Colleen K. Stockdale, MD, MS

8:10 AM - 8:20 AM
Jefferson Ballroom
Introduction of ASCCP President
Speaker: Michael A. Gold, MD

8:20 AM - 10:00 AM
Jefferson Ballroom
Review of Screening Recommendations from Around the World
Moderator: Michael A. Gold, MD

8:20 AM - 8:50 AM
Special Populations
Speaker: James R. Bentley, MD

8:50 AM - 9:15 AM
China
Speaker: Li-Huh Wei, MD

9:15 AM - 9:30 AM
Latin America
Speaker: Carlos H. Perez, MD

9:30 AM - 9:45 AM
International Federation of Cervical Pathology and Colposcopy
Speaker: Walter Prendeville, MD

9:45 AM - 10:00 AM
Europe
Speaker: Fabrizio Bogliatto, MD, PhD

10:00 AM - 10:30 AM
Jefferson Ballroom
Late Breaking Abstracts
Moderator: Michael A. Gold, MD

10:00 AM - 10:15 AM
Factors influencing acceptability of HPV self-sampling in Guatemalan indigenous and nonindigenous communities
Presenter: Jose Jeronimo, MD

10:15 AM - 10:30 AM
Prevalence of gynecological findings discovered during routine well woman examinations for women 40 and over
Presenter: Cynthia Sanchez, MD

10:30 AM - 10:55 AM
Napoleon Ballroom
Break / Visit Exhibits / View Posters
10:55 AM - 11:00 AM                        Jefferson Ballroom
**Presentation of Scientific Awards**
**Moderator:** Michael A. Gold, MD
**Speakers:** Colleen K. Stockdale, MD, MS
             Kevin A. Ault, MD

11:00 AM - 11:20 AM                        Jefferson Ballroom
**Moderator:** Michael A. Gold, MD
**Introduction of Risk Paradigm**
**Speaker:** Mark Schiffman, MD, MPH
             Nicolas Wentzensen, MD, PhD, MS

11:20 AM - 1:30 PM                         Jefferson Ballroom
**Colposcopy Standards**
**Moderator:** Michael A. Gold, MD
**Speakers:** Warner K. Huh, MD
             Nicolas Wentzensen, MD, PhD, MS

1:30 PM
**Adjourn**

---

**Reveal more information during an exam with Smart Colposcopy.**

**Precision biopsy**
- Objective acetowhiteness map
- Biopsy markers
- High contrast filter for vessels

**Unparalleled documentation**
- Dynamic acetowhiteness playback
- High-resolution images and video
- EMR compatible

**Transforms teaching**
- Teaching monitor
- Patient report
- Case libraries and review

**Learn more at dysismedical.com**

---

**DYSIS™**

**Take a test drive**
**Booth #201**
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Abstract Title</th>
<th>Presenting Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ability to Detect High Grade Squamous Anal Intraepithelial Lesions at High Resolution Anoscopy Improves Over Time</td>
<td>Richard John Hillman, MD</td>
</tr>
<tr>
<td>2</td>
<td>Anal Dysplasia in Women with High-Grade Cervical Dysplasia and Cervical Cancer; Is It Time to Start Screening with Cytology and Adjunct hrHPV testing?</td>
<td>Danielle Vicus, MD, FRCSC</td>
</tr>
<tr>
<td>3</td>
<td>Correlation Between Anal Cytology and Biopsy in a Cohort of HIV+ Individuals from New Orleans</td>
<td>Michael E. Hagensee, MD, PhD</td>
</tr>
<tr>
<td>4</td>
<td>Pain During High Resolution Anoscopy (HRA) in Women: The Patient and Provider Perspective</td>
<td>Karla Maguire, MD</td>
</tr>
<tr>
<td>5</td>
<td>Performance of Human Papilloma Virus Genotyping on Anal Cytology Samples: A Validation Study</td>
<td>Amy K. Joiner, MD</td>
</tr>
<tr>
<td>6</td>
<td>Prevalence of Anal Human Papilloma Virus (HPV) in Immunocompetent Colposcopy Patients with High Grade Intraepithelial Neoplasia of the Cervix (CIN2/3) and Vulva (VIN)</td>
<td>Philippe Sauthier, MD</td>
</tr>
<tr>
<td>7</td>
<td>Racial and Geographic Disparities in Anal Cancer Incidence in the US, 2003-2012</td>
<td>Laura Viens, MD, MPH</td>
</tr>
<tr>
<td>8</td>
<td>Risk Factors for Anal Dysplasia in a Cohort of HIV+ Individuals</td>
<td>Michael E. Hagensee, MD, PhD</td>
</tr>
<tr>
<td>9</td>
<td>Differential Gene Expression in Cervical Squamous Intraepithelial Lesions</td>
<td>Lisa B. Spiyda, MD, PhD</td>
</tr>
<tr>
<td>10</td>
<td>Immunohistochemical Study of Six Bronchial Dysplasia Associate Proteins in Uterine Cervical Lesions</td>
<td>Hidenori Sasa, MD</td>
</tr>
<tr>
<td>11</td>
<td>Mullerian Inhibiting Substance Type II Receptor (MISIIR) Expression in Premalignant and Malignant Cervical Lesions</td>
<td>Ahmad Sameer Sanad</td>
</tr>
<tr>
<td>12</td>
<td>p16/Ki67 Double Immunostaining in Triage of HSIL+ Risk Women with HPV Type 16/18-Positive in Primary HPV-Based Screening</td>
<td>Martyna Trzeszcz</td>
</tr>
<tr>
<td>13</td>
<td>Value of Immunohistochemistry in the Diagnosis of Metastatic Adenosquamous Carcinoma of Endocervix: Case Report and Review of Literature.</td>
<td>Alpana Garg, MD</td>
</tr>
<tr>
<td>14</td>
<td>A Model to Predict Risk of Cervical Abnormalities in Primary Care</td>
<td>Laura D. Lipold, MD</td>
</tr>
<tr>
<td>15</td>
<td>A Rapid Cervical Cancer Screening Method – Folate Receptor-Mediated Staining of Cervical Neoplastic Epithelia (CIN2+)</td>
<td>Donghong Li, MD</td>
</tr>
<tr>
<td>16</td>
<td>Adherence to the 2012 National Cervical Cancer Screening Guidelines at the Extremes of Age: A Retrospective Review</td>
<td>Deanna Gek Koon Teoh, MD</td>
</tr>
<tr>
<td>17</td>
<td>An Evaluation of a New HPV test on Cervico-Vaginal Specimens in Liquid Versus Solid Transport Media</td>
<td>Hui Du, MD</td>
</tr>
<tr>
<td>18</td>
<td>Colposcopy Based on Photographs (Colpography). A Complement to Conventional Cytology, as a Screening Strategy in a Colombian Indigenous Population.</td>
<td>Hernan Urdaneta, MD</td>
</tr>
<tr>
<td>19</td>
<td>Comparison of the HPV Genotypes in the Tissues of the Colposcopically Visible and Invisible CIN3</td>
<td>Xinfeng Qu, MD</td>
</tr>
<tr>
<td>20</td>
<td>Conventional Pap Smear Cervical Screening in 11 Rural Counties in Hainan Providence, China: Analysis of TBS Reporting Rates for 218,195 Screened Women</td>
<td>Baowen Zheng, MD</td>
</tr>
<tr>
<td>21</td>
<td>Deconstructing “Histologic HSIL”: Potential Harm of Failing to Distinguish Grades of CIN for Women of Different Ages</td>
<td>Katie Keneffick Crean, MD</td>
</tr>
<tr>
<td>22</td>
<td>Development of CerMark™ Multiplex Protein Biomarker Test for Cervical Cancer</td>
<td>Nam W Kim, PhD</td>
</tr>
<tr>
<td>23</td>
<td>Development of a Novel Self-Collection Device for Cervical Cytology</td>
<td>Nam W Kim, PhD</td>
</tr>
<tr>
<td>24</td>
<td>Differences in Follow-up of Abnormal Cervical Cancer Screening Results in Faculty Versus Resident Obstetrics/Gynecology (OBGYN) Clinics</td>
<td>Frances W Grimstad, MD</td>
</tr>
<tr>
<td>25</td>
<td>Factors Leading to Delay in the Diagnosis of Advanced Cervical Cancer</td>
<td>Michael S Kinson, MD, MA</td>
</tr>
<tr>
<td>26</td>
<td>Frequency of Adequate Endometrial Biopsy in Evaluation of Postmenopausal Women with Benign Endometrial Cells on Pap Test</td>
<td>Jeffrey Hastings, MD</td>
</tr>
<tr>
<td>27</td>
<td>HPV DNA Testing in Cervical Cancer Screening: Challenges at Colposcopy and Beyond.</td>
<td>Ida Suzani Ismail-Pratt, MD</td>
</tr>
<tr>
<td>28</td>
<td>Human Papillomavirus Reporting Rates in the Largest Women Hospital in China</td>
<td>Xiang Tao, MD, PhD</td>
</tr>
<tr>
<td>29</td>
<td>Impact of Invitation and Reminder Letters on Cervical Cancer Screening Participation Rate in an Organized Screening Program</td>
<td>Rachel Kupets, MD</td>
</tr>
<tr>
<td>30</td>
<td>Improving Provider Compliance to Current Cervical Cancer Screening and Abnormal Cervical Cytology Management Guidelines</td>
<td>Ericka L. Vander Sys, DNP, CNM</td>
</tr>
<tr>
<td>31</td>
<td>Introducing HPV Sampling into a Public Sector Screening Program in El Salvador</td>
<td>Miriam Cremer, MD, MPH</td>
</tr>
<tr>
<td>32</td>
<td>Is it Appropriate to Delay Colposcopic Referral of Women with Low Grade Cytologic Abnormalities?</td>
<td>Rachel Kupets, MD</td>
</tr>
<tr>
<td>34</td>
<td>Knowledge of Cervical Cancer and Pap Smears in Uyghur Women from Xinjiang, China</td>
<td>Fatima Mijit</td>
</tr>
<tr>
<td>35</td>
<td>Low Resource Cervical Cancer Screening in El Salvador: Comparing Visual Screening with Acetic Acid (VIA) and Pap Smear Use</td>
<td>Salena Meyer Loredo, MPH</td>
</tr>
<tr>
<td>36</td>
<td>Patient and Provider Characteristics Associated with Cervical Cancer Under-Screening in an Urban HIV Clinic</td>
<td>Kristen Lee, BA</td>
</tr>
<tr>
<td>37</td>
<td>Predictors of Positive Margins at Time of Loop Electrosurgical Excision Procedure</td>
<td>Jill Liss, MD</td>
</tr>
<tr>
<td>38</td>
<td>Predictors of Suboptimal Loop Electrosurgical Excisional Procedure</td>
<td>Kelsey L. Arbogast, MD</td>
</tr>
<tr>
<td>39</td>
<td>Prevention of Post-Leep Cervico-Vaginal Infection</td>
<td>Fabrizio Bogliatto</td>
</tr>
<tr>
<td>40</td>
<td>Progression of Low-Grade Cervical Dysplasia in Women Older 50 with CDC-Defined AIDS Illness. A Pilot Study</td>
<td>Sharise T Richardson, MD</td>
</tr>
<tr>
<td>41</td>
<td>Risk Factor Associated with Human Papillomavirus Infection Among Uyghur Women in Xinjiang</td>
<td>Guzalnur Abliz, Postdoctor</td>
</tr>
<tr>
<td>42</td>
<td>Risk Factors Correlating to CIN 2/3 or Cervical Cancer in Women Under 25 Relative to Screening Policy</td>
<td>Robin R. Black, OGNP</td>
</tr>
<tr>
<td>43</td>
<td>Role of 6 Week Post Treatment MRI of the Pelvis in Patients with Locoregionally Advanced Cervical Cancer Following CURATIVE Chemotherapy and Radiation</td>
<td>Kathleen Gong, MD</td>
</tr>
<tr>
<td>44</td>
<td>Role of Complementary Cytology, Colposcopy and Histopathology in Detecting Premalignant and Malignant Lesions of Cervix</td>
<td>Akanksha Mangla</td>
</tr>
<tr>
<td>45</td>
<td>The Expression of Local P16,Ki67 Gene and Fas Expression After Focused Ultrasound Treatment of CIN</td>
<td>Chengzhi Li, Doctor</td>
</tr>
<tr>
<td>46</td>
<td>The Older Woman: Experience with ASCCP Guidelines in Underserved Women</td>
<td>Helen E. Cejtin, MD</td>
</tr>
<tr>
<td>47</td>
<td>Cervical Digital Photography: An Alternative Method to Colposcopy</td>
<td>Elise de Castro Hillmann</td>
</tr>
<tr>
<td>48</td>
<td>Clinical Outcomes of the Conservative Management of High Grade Squamous Intraepithelial Lesions in Young Women</td>
<td>Leslie Ann Sadownik, MD, MEd, FRCSC</td>
</tr>
<tr>
<td>49</td>
<td>Diagnostic Accuracy of Colposcopically Directed Biopsy and Loop Electrosurgical Excision Procedure in Cervical Lesions</td>
<td>Fengyi Xiao, MD</td>
</tr>
<tr>
<td>50</td>
<td>Digital Colposcopy Generation II</td>
<td>Serhiy Poustovarov</td>
</tr>
<tr>
<td>51</td>
<td>Dynamic Spectral Imaging Colposcopy: Prospective Results from Two IMPROVE-COLPO Study Community Clinics</td>
<td>Emmanouil Papagiannakis, PhD</td>
</tr>
<tr>
<td>52</td>
<td>Expectant Management of CIN 2 and 3 in Young Women</td>
<td>Rachel Darche, MD</td>
</tr>
<tr>
<td>53</td>
<td>Feasibility to Diagnose Cervical Cancer During Colposcopy Using Fabric-Based Minimally Invasive Biopsy Devices</td>
<td>Praveena Yetur, MD</td>
</tr>
<tr>
<td>54</td>
<td>Improving Resident Colposcopy Education and Patient Compliance in an Urban Academic Medical Center</td>
<td>Kimberly S. Gecsi, MD</td>
</tr>
<tr>
<td>55</td>
<td>Improving Workflow and Documentation with a Cloud Based Mobile Colposcope</td>
<td>Jonah Mink, MD</td>
</tr>
<tr>
<td>56</td>
<td>Photo-Micrographic Comparison of Spiral-Bristle and Fabric-Based Minimally Invasive Excervical Biopsies Relative to Punch Biopsy</td>
<td>Praveena Yetur, MD</td>
</tr>
<tr>
<td>57</td>
<td>The Pathologic Analysis of LSIL and ASCUS Under the Guide of Colposcopy</td>
<td>Eunseop Song, MD, PhD</td>
</tr>
<tr>
<td>58</td>
<td>Which Colposcopies Should Include Endocervical Curettage?</td>
<td>Robert G. Pretorius, MD</td>
</tr>
<tr>
<td>59</td>
<td>Who is Going to Colposcopy? A Montérégie Region Study.</td>
<td>Elise de Castro Hillmann, PhD</td>
</tr>
<tr>
<td>60</td>
<td>Why Cervical Cancer is Missed at Colposcopy: To-Date Findings of the IMPROVE-COLPO Community Study</td>
<td>Emmanouil Papagiannakis, PhD</td>
</tr>
<tr>
<td>61</td>
<td>Analysis of HPV Infection and Abnormal Cervical Cytology During the Postpartum Period</td>
<td>Tae Jin Kim, MD, PhD</td>
</tr>
<tr>
<td>62</td>
<td>Are Risk Factors Associated with HPV Status in HIV+ Women with Atypical Squamous Cells of Undetermined Significance Cervical Cytology?</td>
<td>JoNeil E. Potter, PhD, RN</td>
</tr>
<tr>
<td>63</td>
<td>Defining the HPV-Associated Cancer Burden in the United States</td>
<td>Laura Viens, MD, MPH</td>
</tr>
<tr>
<td>64</td>
<td>Prevalence of High Risk Human Papilloma Virus Infection in Young Primiparous Women After First Delivery: Study From North India</td>
<td>Alpana Garg, MD</td>
</tr>
<tr>
<td>65</td>
<td>Study on the Role of TLR3 in Cervical HPV16 Persistent Infection and Cervical Lesions</td>
<td>Quanxin Qu, Dr</td>
</tr>
<tr>
<td>66</td>
<td>The Prevalence of HPV Infection in the Semen Among Korean Men and the Effect of HPV Infection on Sperm Parameters</td>
<td>Tae Jin Kim, MD, PhD</td>
</tr>
<tr>
<td>67</td>
<td>Understanding the Sexual Behaviors of Women That May Put Them at Risk for HPV-Related Neoplasias</td>
<td>Amita Kulkarni, BA</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Author(s)</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>68</td>
<td>ALA-PDT in the Treatment of Persistent HR-HPV Infection HPV Infection and its Associated Cervical Lesions: A Prospective Pilot Study</td>
<td>Qisang Guo, MD</td>
</tr>
<tr>
<td>69</td>
<td>Oral and Cervical HPV Infection in HIV-Positive Women in Mexico and Nicaragua</td>
<td>Milagros Perez Quintanilla, MD</td>
</tr>
<tr>
<td>70</td>
<td>Quality Assurance Program for HPV Testing in Korea</td>
<td>Tae Jin Kim, MD, PhD</td>
</tr>
<tr>
<td>71</td>
<td>Race/Ethnicity and HPV Types in Cervical Cells</td>
<td>Lisa B. Spiryda, MD, PhD</td>
</tr>
<tr>
<td>72</td>
<td>Two-Year Cumulative Prevalence of HR-HPV in 35-60 Year Old Women by Age and Sexual History: Results from the Hip in Perimenopause (HIP) Study</td>
<td>Michelle Silver, PhD, ScM</td>
</tr>
<tr>
<td>73</td>
<td>A Randomized Intervention Study to Evaluate Whether Electronic Messaging Can Increase HPV Vaccine Uptake and Knowledge</td>
<td>Alice Richman, PhD, MPH</td>
</tr>
<tr>
<td>74</td>
<td>Human Papillomavirus Vaccine Completion in Pediatric Patients and the Role of Follow-up Appointment Scheduling</td>
<td>Rebecca Leslie Sabates, MS</td>
</tr>
<tr>
<td>75</td>
<td>Knowledge and Acceptance of Human Papilloma Virus Vaccine among Hispanic Females with Abnormal Cervical Cytology Attending Colposcopy Clinics in Puerto Rico</td>
<td>Josefina Romaguera, MD</td>
</tr>
<tr>
<td>76</td>
<td>Provider Barriers to HPV Vaccination: An Educational Intervention, Part 1</td>
<td>Dara Matthew, MD</td>
</tr>
<tr>
<td>77</td>
<td>Providers’ Attitudes Towards Introduction of Human Papillomavirus Vaccination Among Eligible Postpartum Women</td>
<td>Abbey B. Berenson, MD, PhD</td>
</tr>
<tr>
<td>78</td>
<td>A Review of Cervical and Vaginal Outcomes in a Cohort of Women with History of In-Utero Diethylystilbestrol Exposure</td>
<td>A. Mitch Dizon, MD</td>
</tr>
<tr>
<td>79</td>
<td>Behçet Syndrome is an Import Albeit Rare Painful Vulvar Ulcer, Case Presentation, and Discussion of Management</td>
<td>Bunan Alnaif, MD</td>
</tr>
<tr>
<td>80</td>
<td>Evaluation and Management of Patients with Irritative Vulvar Complaints at Parkland Hospital</td>
<td>Sarah Bedell, MD</td>
</tr>
<tr>
<td>81</td>
<td>Successful Treatment of 178 Patients with Resistant and Refractory Vaginitis with a Single Session of a Novel Pegylated Vanadium Compound</td>
<td>Kiumars Khodabakhshi Pirkalani</td>
</tr>
<tr>
<td>82</td>
<td>Symptoms Associated with Female Genital Schistosomiasis in Young South African Women. A Cross Sectional Study.</td>
<td>Hashini Galappaththi-Arachchige, MD</td>
</tr>
<tr>
<td>83</td>
<td>Clinical Responses to Imiquimod Applied to Postoperative Women With High-Grade Vagina Intraepithelial Neoplasia</td>
<td>Jia Ying</td>
</tr>
<tr>
<td>84</td>
<td>Retrospective Evaluation of Clinicopathological Features and Diagnostic and Treatment Protocols of Primary Vaginal Malignancy</td>
<td>Mehmet Kulhan, Asst. Prof.Dr.</td>
</tr>
<tr>
<td>85</td>
<td>Age Related Outcomes in Vulvar Cancer</td>
<td>Camille C. Gunderson, MD</td>
</tr>
<tr>
<td>86</td>
<td>Presence of Human Papillomavirus (HPV) in Vulvar Squamous Cell Carcinoma (VSCC) in Chinese Patients</td>
<td>Jiajia Li, PhD</td>
</tr>
<tr>
<td>87</td>
<td>Use of GATA-3 and Uroplakin-II in Differentiating Primary Cutaneous Vulvar Paget Disease from Pagetoid Urothelial Intraepithelial Neoplasia</td>
<td>Kent Newsom, DO</td>
</tr>
<tr>
<td>88</td>
<td>Vulvar Carcinoma in Patients Younger than 40 years: Is it More Aggressive? - Case Report</td>
<td>Morva Tahmasbi Rad, Specialist</td>
</tr>
<tr>
<td>89</td>
<td>Consensus Survey by Vulvodynia Experts on Outcome Measures to Use in Chronic Pain Multicenter Clinical Trials</td>
<td>Candace Susanne Brown, Phar, MD</td>
</tr>
<tr>
<td>90</td>
<td>In Vitro Localized Provoked Vulvodynia (LPV) Model Implicates Imiquimod as a Neuroinflammatory Trigger of Localized Allodynia</td>
<td>David C. Foster, MD, MPH</td>
</tr>
</tbody>
</table>
American Medical Women’s Association

ASCCP, The Society for Lower Genital Tract Disease

ASCCP, The Society for Lower Genital Tract Disease, is a professional Society serving a variety of healthcare professionals in the field. Membership to the Society includes several benefits like a free subscription to the Journal of Lower Genital Tract Disease, weekly e-newsletters, discounted registration on educational meetings and courses, and much more.

BD Life Sciences

Cancer Genetics

Cancer Genetics Inc. is an emerging leader in personalized cancer diagnostics. Our tests target difficult to diagnose hematological, urogenital and HPV-associated cancers. They are designed to guide the prognosis and treatment of these cancers with the goal of improving outcomes for patients. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals and biopharmaceutical companies. Our state-of-the-art reference labs are CLIA certified and CAP accredited in the US and have licensure from several states including New York State.

Cervivor

Cervivor is a community, a learning tool, an advocacy resource, and an online retreat for healing, connecting and thriving beyond cervical cancer.

Calmoseptine® Ointment

Calmoseptine® Ointment protects and helps heal skin irritations from moisture such as urinary and fecal incontinence. It is also effective for irritations from perspiration, wound drainage, fecal & vaginal fistulas and feeding tube site leakage. Calmoseptine® temporarily relieves discomfort and itching. Free samples at our booth!
CooperSurgical is a leading provider of innovative medical devices and procedure oriented solutions that advance the standard of care for women. Our highly reliable and clinically relevant products and services facilitate the delivery of enhanced outcomes for your patients regardless of the clinical setting. Come visit us at our booth to interact with our industry leading solutions and experience why CooperSurgical is at the forefront of women's health care.

Cyalume Technologies, Inc. is the recognized leader in providing innovative chemical light technology solutions to numerous industries. Applying our expertise to healthcare, the SpecuLume™ self-illuminating disposable vaginal speculum provides brilliant light where needed most without requiring batteries or electricity. Cyalume’s chemilluminated medical devices; patient care in a new light!

DySIS™ Next Generation Colposcope with Advanced Cervical Scan – Color-coded DySISMap™ objectively measures the most acetowhite areas to help guide cervical biopsies and provides the ultimate exam documentation including hi-res video, images, EMR interface and DySISMap. Visit booth 201 to learn how to become a DySIS Cervical Center of Excellence www.dysismedical.com

GY Highland Biotech LLC is promoting its innovative cervical cancer detecting technique, Folate Receptor Medicated Staining Solution (FRDTM), worldwide for the early detection of abnormal lesions (CIN2+). Results are determined immediately (60 seconds). Meta-analysis has revealed that the FRDTM has a sensitivity and specificity of 85% for detecting CIN2+.

Gynex is one of the leading suppliers of colposcopes, instruments and products for Ob/Gyn physicians. We pride ourselves in our continued commitment to innovation and quality, all at reasonable prices and ultimately, to the enhanced care and improved health of women everywhere.

The Gynocular is a high quality colposcope. The Gynocular has cutting edge optics and LED technology. It is lightweight and battery driven. A smartphone can be connected to the Gynocular for image capture. The T2D application allows for a structured colposcopy exam, direct referral as well as log book and cloud storage.
Histologics LLC continues to offer innovative, compassionate options for colposcopy. The proprietary fabric-tipped (Kylon®) exocervical Gynecological biopsy devices (SoftBiopsy®), endocervical curettes (SoftECC®) and the bristle biopsy brush - SpiraBrush CX® are award-winning, FDA compliant disposable devices. Each provide an affordable, efficient, and gentle “rotational” approach to colposcopic biopsy.

International Anal Neoplasia Society
PO Box 2023
Montgomery Village, MD 20886
301-602-3256
goldstone.stephen@gmail.com
www.ians.memberlodge.org

The world’s first professional society devoted to prevention and treatment of AIN and anal cancer. IANS mission is to provide a forum for exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia among individuals with a broad spectrum of background, viewpoints and geographic origin.

Lutech Industries, Inc.
105 Remington Blvd
Ronkonkoma, NY 11779
631.676.7432
j.fink@lutechmedical.com
www.lutechmedical.com

Lutech Industries Inc. brings together innovative, cutting edge technology with cost conscious strategies. Affordable quality medical equipment that allows providers to care for patients the way they are meant to. Dedicated to making your job easier, Lutech offers repair services and strong technical support. Your partner in advancing medical care!

Merck
2000 Galloping Hill
Kenilworth, NJ 07033
267.305.0361
nand.kumar@merck.com
www.merck.com

For 125 years, Merck has been a global health care leader working to help the world be well.

National Association of Nurse Practitioners in Women’s Health
505 C Street, NE
Washington, DC 20002
202.543.9693 x 1
info@npwh.org
www.npwh.org

The National Association of Nurse Practitioners in Women’s Health’s (NPWH) strives to ensure the provision of high-quality health care to all women by WHNPs and other women’s health-focused APRNs. NPWH supports APRNs by providing educational resources to increase clinical competencies, fostering evidence-based practice, and advocating for the best health care policies for women and APRNs. More information is available at www.npwh.org.

Roche
9115 Hague Road
Indianapolis, IN 46250
317.521.3376
lisa.almert@roche.com
www.hpv16and18.com

A global pioneer in pharmaceuticals and diagnostics, Roche is focused on advancing science to improve people’s lives. Our personalized healthcare strategy aims to fit the right treatment to each patient in the best way possible. Molecular diagnostics like the cobas® HPV Test focus on increasing medical value and testing efficiency.
Seiler Instrument
3433 Tree Court Industrial Boulevard
St. Louis, MO 63122
314.218.6344
amoroney@seilerinst.com
www.seilermicro.com

Optical instruments have been a Seiler family tradition since 1913. Seiler Colposcopes come equipped with Apochromatic Lenses for superior clarity, the brightest light sources on the market and smooth, fluid movement for the ultimate in mobility. Seiler stands behind our products with a lifetime warranty on the optics and mechanics.

The International Federation of Cervical Pathology and Colposcopy
1530 Tilco Drive, Suite C
Frederick, MD 21704
ifcpc@ascahp.org
www.ifcpc.org

The IFCPC is the Global Federation for Colposcopy and Cervical Pathology with 47 member National Societies. Created in 1972 the next World Congress will be in Orlando, April 2-7th 2017. The scientific content will be global with a US and Latin American emphasis. Please come!

Utah Medical Products, Inc.
7043 South 300 West
Midvale, UT 84047
801.369.4125
tpaulos@utahmed.com
www.utahmed.com

Utah Medical Products’ specialized gynecology products provide excellent clinical results. Finesse®+ electrosurgical systems with integrated smoke evacuation provide high performance in a compact footprint that is ideal for the office. When used with the unique UtahLoop electrodes, Finesse+ Systems provide clean specimens for consistently conclusive histopathology.

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. Our solutions are designed to help professionals build clinical competency and improve practice and patient care. We offer evidence-based medical, nursing and allied health content and clinical decision support tools.

Zinnanti Surgical Design Group, Inc. combines experience in device development, medical training and research to create innovative surgical devices that improve safety, effectiveness and efficiency. We specialize in high quality advanced energy devices with dual function. We work closely with surgeons to learn from their experience and provide solutions. Our patented design technology, “Smoke-Evac Fusion”, is the only product available for simultaneous evacuation of both smoke and fluids for all types of surgery.
ASCCP Colposcopy Mentorship Program (CMP)

Earn Your Certificate of Completion in Colposcopy—Sign-Up Today!

www.asccp.org
Save the Date!

IFCPC 2017 World Congress
for Cervical Pathology and Colposcopy
April 4-7, 2017 | Orlando, Florida
www.ifcpc2017.com

Hosted by ASCCP